Clinical Trial Update: 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF [Phase 2]

View source ↗

Summary

Phase 2 trial comparing 12 weeks of ledipasvir/sofosbuvir with weight-based ribavirin to 24 weeks of ledipasvir/sofosbuvir in patients with HIV-1 infection and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Conditions: HIV-1 Infection, Hepatitis C | Phase 2 | Status: TERMINATED | Results posted: 2018-02-15